ABARCEO PHARMA AB
Abarceo Pharma is a spin out of Lund University Diabetes Center and is located in Malmo Sweden. Scientific founders Prof. Claes Wollheim, MD and Associate Prof. Albert Salehi are world-class experts in beta cell biology. Abarceo Pharma is a Lund University Holding company and was founded in December 2017. The company is dedicated to developing novel therapeutics for type-2 diabetes based upon a deep molecular and genetic understanding of the disease.
ABARCEO PHARMA AB
Industry:
Biotechnology Pharmaceutical Therapeutics
Address:
Malmö, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.abarceo.com
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins
Current Employees Featured
Founder
Official Site Inspections
http://www.abarceo.com
- Host name: webcluster2.webpod13-cph3.one.com
- IP address: 46.30.213.125
- Location: Copenhagen Denmark
- Latitude: 55.6786
- Longitude: 12.5589
- Timezone: Europe/Copenhagen
- Postal: 1052
More informations about "Abarceo Pharma AB"
Abarceo Pharma | Making mitochondria healthy
Abarceo Pharma, a pre-clinical stage company, is developing a platform for the treatment of mitochondrial diseases, with an initial focus on Type 2 Diabetes (T2D). Abarceo Pharma is a spin-out of Lund University Diabetes Center …See details»
Abarceo Pharma AB - Crunchbase Company Profile & Funding
Abarceo Pharma is a spin out of Lund University Diabetes Center and is located in Malmo Sweden. Scientific founders Prof. Claes Wollheim, MD and Associate Prof. Albert Salehi are …See details»
Abarceo Pharma AB - LinkedIn
Abarceo Pharma AB | 615 followers on LinkedIn. Developing the first disease modifying and durable treatment for type 2 and type 1 diabetes. | Abarceo is a preclinical stage company. …See details»
Abarceo Pharma AB - The Org
Abarceo Pharma is a spin out of Lund University Diabetes Center and is located in Malmo Sweden. Scientific founders Prof. Claes Wollheim, MD and Associate Prof. Albert Salehi are …See details»
Abarceo Pharma - Craft
Abarceo Pharma is a company that develops therapeutics for type-2 diabetes. It identifies VDAC1 as a key target in type-2 diabetes and develops antibodies and small-molecule inhibitors …See details»
Abarceo Pharma AB Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Abarceo Pharma AB of Malmö, Skåne. Get the latest business insights from Dun & Bradstreet.See details»
Abarceo Pharma AB - Malmö, Sweden - bionity.com
Abarceo Pharma has identified a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to …See details»
Team | Abarceo Pharma
Abarceo Pharma is a Lund University Holding company and was founded in December 2017. Abarceo Pharma has identified a novel diabetes target VDAC1 located on beta cells and a …See details»
Abarceo AB - Drug pipelines, Patents, Clinical trials - Synapse
Last update 23 Jan 2025. Abarceo AB. Startups |See details»
Abarceo Pharma AB - Home
Abarceo Pharma AB. Abarceo Pharma is developing a small molecule technology platform for the treatment of mitochondrial dysfunction, with an initial focus on T2D. KONTAKT CEO Kristian …See details»
Abarceo Pharma - VentureRadar
Abarceo Pharma is a spin-out of Lund University Diabetes Center and is located in Malmo Sweden. Scientific founders Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi are …See details»
Abarceo Pharma | Innovation at Lund University
Abarceo Pharma has identified a novel diabetes target and has elucidated the key to the revival of dysfunctional beta cells enabling a resetting of the beta cell to a functional and healthy state. …See details»
About | Abarceo Pharma
Abarceo Pharma is a spin-out of Lund University Diabetes Center founded in 2017 by Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi world-renowned scientists in diabetes …See details»
Abarceo Pharma AB - Contacts, Employees, Board Members
Abarceo Pharma has identified a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic. ... Experience the new Crunchbase, powered by …See details»
Home 2 | Abarceo Pharma
Abarceo Pharma is a spin-out of Lund University Diabetes Center and is located in Malmo Sweden. Scientific founders Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi are …See details»
Adam Bruce - Chairman at Abarceo Pharma AB - The Org
Since July 2020, Adam has been the Chairman of Abarceo Pharma, where efforts are directed towards innovative solutions for Type 2 Diabetes. Adam also owns WaveSeven AB, active …See details»
Pipeline | Abarceo Pharma
Abarceo Pharma AB. Medeon Science Park Per Albin Hanssons vä 41, 205 12 Malmö, Sweden. Email: [email protected]. Abarceo Pharma is a Lund University Holding company and was …See details»
Abarceo Pharma AB - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Mar 1, 2021: Venture Round - …See details»
News | Abarceo Pharma
Nov 14, 2024 Abarceo Pharma is a Lund University Holding company and was founded in December 2017 by Scientific founders Prof. Claes Wollheim, MD, and Associate Prof. Albert …See details»
Science | Abarceo Pharma
Abarceo Pharma is a spin-out of Lund University Diabetes Center founded in 2017 by Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi world-renowned scientists in diabetes …See details»